In a report issued on November 1, Sean Lavin from BTIG maintained a Hold rating on Atricure (ATRC). The company’s shares closed on Friday at $31.35.
Lavin noted:
“The company’s Q3 earnings call was straightforward, following the pre- announcement of results on 10/3.”
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 12.3% and a 61.0% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.
Atricure has an analyst consensus of Strong Buy, with a price target consensus of $38.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.49 and a one-year low of $14.88. Currently, Atricure has an average volume of 248.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AtriCure, Inc. engages provision of treatment of atrial fibrillation and left atrial appendage. It operates through the following geographical segments: United States, Europe, Asia, and Other International.
